Beihai Gofar Chuanshan Biological Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Beihai Gofar Chuanshan Biological Co., Ltd. carries a market capitalization of 3.08B, placing it among publicly traded companies globally. Its enterprise value stands at 1.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.08B |
| Enterprise Value | 1.68B |
Share Statistics
Beihai Gofar Chuanshan Biological Co., Ltd. currently has 524.20M shares outstanding.
| Shares Outstanding | 524.20M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 5.54, and the price-to-book ratio stands at -36.44.
| PE Ratio | N/A |
| PS Ratio | 5.54 |
| PB Ratio | -36.44 |
| P/TBV Ratio | 2.85 |
| P/FCF Ratio | 214.84 |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 5.28 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 157.16 |
Financial Position
Beihai Gofar Chuanshan Biological Co., Ltd. maintains a current ratio of 3.69, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.95, indicating elevated leverage, while an interest coverage ratio of -6.15 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.69 |
| Quick Ratio | 1.01 |
| Debt / Equity | 4.95 |
| Debt / EBITDA | -2.51 |
| Interest Coverage | -6.15 |
Financial Efficiency
| Return on Equity (ROE) | -117.68 |
| Return on Assets (ROA) | -8.41 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -161.66 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.82 |
Taxes
Over the trailing twelve months, Beihai Gofar Chuanshan Biological Co., Ltd. has paid -840,330.01 in income taxes, reflecting an effective tax rate of 9.57.
| Income Tax | -840,330.01 |
| Effective Tax Rate | 9.57 |
Stock Price Statistics
Beihai Gofar Chuanshan Biological Co., Ltd.'s stock has gained approximately 4.82143% over the past 52 weeks. The 50-day moving average sits at 6.41, while the 200-day moving average is 6.33.
| Beta (5Y) | N/A |
| 52-Week Price Change | 4.82143% |
| 50-Day Moving Average | 6.41 |
| 200-Day Moving Average | 6.33 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Beihai Gofar Chuanshan Biological Co., Ltd. generated 317.46M in revenue and converted that into -83.58M in net income, yielding earnings per share of -0.26. EBITDA reached -15.42M, while operating income came in at -15.42M.
| Revenue | 317.46M |
| Gross Profit | 77.60M |
| Operating Income | -15.42M |
| Pretax Income | -82.87M |
| Net Income | -83.58M |
| EBITDA | -15.42M |
| EBIT | -15.42M |
| Earnings Per Share (EPS) | -0.26 |
Balance Sheet
Beihai Gofar Chuanshan Biological Co., Ltd. holds 133.60M in cash and equivalents against 38.69M in total debt, resulting in a net debt position of -132.64M. Total book value stands at -48.23M, with working capital of 354.76M providing operational flexibility.
| Cash & Cash Equivalents | 133.60M |
| Total Debt | 38.69M |
| Net Debt | -132.64M |
| Equity (Book Value) | -48.23M |
| Book Value Per Share | -0.15 |
| Working Capital | 354.76M |
Cash Flow
After subtracting -8.18M in capital expenditures, free cash flow totaled -8.18M - equivalent to -0.03 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -8.18M |
| Free Cash Flow | -8.18M |
| FCF Per Share | -0.03 |
Margins
Beihai Gofar Chuanshan Biological Co., Ltd. operates with a gross margin of 24.44, reflecting its pricing power and cost economics. The operating margin of -4.86 and net profit margin of -26.33 provide insight into operational efficiency.
| Gross Margin | 24.44 |
| Operating Margin | -4.86 |
| Pretax Margin | -26.11 |
| Profit Margin | -26.33 |
| EBITDA Margin | -4.86 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.31 |
| FCF Yield | 0.47 |
Stock Splits
Beihai Gofar Chuanshan Biological Co., Ltd.'s most recent stock split took place on June 7, 2006 with a 5:7 split ratio.
| Last Split Date | 6/7/2006 |
| Split Ratio | 5:7 |
Scores
Beihai Gofar Chuanshan Biological Co., Ltd. posts an Altman Z-Score of 6.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.18 |